Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.
Launched by HOSPITAL ARNAU DE VILANOVA · Aug 13, 2008
Trial Information
Current as of June 05, 2025
Unknown status
Keywords
ClinConnect Summary
We will perform non-invasive techniques (carotid Intima-Media Thickness, CAC score and ankle-brachial index) to individuals at intermediate cardiovascular risk.With these results, we will classify participants in: no atherosclerosis, mild, moderate and severe atherosclerosis, and therapeutic targets will be set according to pre-defined algorithms. The end-point will be the course of atherosclerosis measured by cIMT/CAC score (2 years) and the incidence of CVD at 5 years of follow-up.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- One or more of the following:
- • Familiar History of early-onset cardiovascular disease (male \< 55 or female \< 65).
- • Type 2 Diabetes mellitus or type 1 with microalbuminuria.
- • Essential High Blood Pressure.
- • Chronic Kidney Disease.
- • Primary hyperlipidemia.
- The presence of two or more of the following:
- • Current smoker.
- • Physical inactivity.
- • High blood pressure (recently diagnosed).
- • Abdominal perimeter: \> 102 cm. males; \> 88 cm. females.
- • Total cholesterol \> 240 mg/dL.
- • HDL cholesterol ≤ 40 mg/dL males, ≤ 50 mg/dL females.
- Exclusion Criteria:
- • Age \< 40 or \> 74 years old.
- • Previous Cardiovascular Event.
About Hospital Arnau De Vilanova
Hospital Arnau de Vilanova is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a collaborative approach to research, the hospital serves as a vital center for clinical studies across various therapeutic areas. Leveraging state-of-the-art facilities and a multidisciplinary team of experts, Hospital Arnau de Vilanova aims to contribute to the development of new treatments and therapies that enhance the quality of life for patients both locally and globally. Its focus on ethical standards and rigorous scientific methodology ensures the integrity and reliability of its research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lleida, Catalunya, Spain
Patients applied
Trial Officials
Elvira Fernandez, MD,PhD
Principal Investigator
Hospital Arnau de Vilanova
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials